Q4 FY2025 · ended Dec 31, 2025 · Revenue $-499,950, -25529.8% YoY · Filed Mar 3, 2026
ABVC BioPharma, Inc. (ABVC) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$7.6 million. As of Jun 30, 2026 it held $2.6 million in cash and investments and $1.8 million in total debt.
Revenue
$-499,950
-25529.8% vs year-ago quarter
Net income
$-736,934
+67.3% vs year-ago quarter
Operating cash flow
$-244,413
+72.7% vs year-ago quarter
Free cash flow
$-7.64M
EPS
$-0.03
+76.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
26.65M
+13.2% vs year-ago quarter
Net cash
$761,009
Q2 FY2026
Operating margin
439.8%
Q4 FY2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABVC (Nasdaq), ECOC (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Fremont, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1173313
- Former names
- American BriVision (Holding) Corp (until Apr 8, 2021); METU BRANDS, INC. (until Jan 8, 2016); Ecology Coatings, Inc. (until Sep 2, 2015); ECOLOGY COATINGS, INC. (until Sep 2, 2015); OCIS CORP (until Jun 13, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | -$499,950 | $795,950 | — |
| Operating income | -$779,526 | -$1.6M | -$2.2M | -$2.0M | -$2.3M |
| Net income | -$736,934 | -$1.6M | -$2.8M | -$2.0M | -$2.3M |
| Diluted EPS | -$0.03 | -$0.06 | -$0.11 | -$0.09 | -$0.13 |
| Operating cash flow | -$244,413 | -$894,243 | -$587,582 | -$964,710 | -$894,174 |
| Free cash flow | -$7.6M | — | — | — | — |
| Total assets | $19.4M | $19.7M | $21.1M | $21.2M | $16.2M |
| Total liabilities | $7.1M | $6.9M | $7.8M | $6.7M | $6.8M |
| Stockholders' equity | $10.3M | $10.8M | $11.1M | $12.1M | $7.0M |
| Cash and investments | $2.6M | $2.0M | $2.6M | $3.0M | $3.3M |
| Total debt | $1.8M | $1.9M | $2.7M | $1.2M | $1.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Agreement ended, New debt, Unregistered share sale, Shareholder vote results, Regulation FD disclosure
|
Nov 2, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Regulation FD disclosure
|
Aug 27, 2026 | Aug 27, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K/A |
Amended current report
Other events
|
Aug 12, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Other events
|
Aug 4, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Auditor change
|
Jul 2, 2026 | Jul 2, 2026 |
All 795 ABVC BioPharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.